Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 274

1.

Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.

Gaikwad T, Ghosh K, Kulkarni B, Kulkarni V, Ross C, Shetty S.

Eur J Pharmacol. 2013 Jun 15;710(1-3):80-4. doi: 10.1016/j.ejphar.2013.04.006. Epub 2013 Apr 16.

PMID:
23602689
[PubMed - indexed for MEDLINE]
2.

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.

Ozer N, Cam N, Tangurek B, Ozer S, Uyarel H, Oz D, Guney MR, Ciloglu F.

Heart Vessels. 2010 Mar;25(2):155-62. doi: 10.1007/s00380-009-1177-7. Epub 2010 Mar 26.

PMID:
20339978
[PubMed - indexed for MEDLINE]
3.

Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.

Shalia KK, Doshi SM, Parikh S, Pawar PP, Divekar SS, Varma SP, Mehta R, Doctor T, Shah VK, Saranath D.

J Assoc Physicians India. 2012 Dec;60:34-8.

PMID:
23781667
[PubMed - indexed for MEDLINE]
4.
5.

Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.

Natarajan S, Ponde CK, Rajani RM, Jijina F, Gursahani R, Dhairyawan PP, Ashavaid TF.

Pharmacol Rep. 2013;65(5):1375-82.

PMID:
24399734
[PubMed - indexed for MEDLINE]
Free Article
6.

Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.

Lu Y, Yang J, Zhang H, Yang J.

Clin Pharmacokinet. 2013 Jul;52(7):567-81. doi: 10.1007/s40262-013-0054-9.

PMID:
23515956
[PubMed - indexed for MEDLINE]
7.

Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.

Lund K, Gaffney D, Spooner R, Etherington AM, Tansey P, Tait RC.

Br J Haematol. 2012 Jul;158(2):256-61. doi: 10.1111/j.1365-2141.2012.09150.x. Epub 2012 May 10.

PMID:
22571356
[PubMed - indexed for MEDLINE]
8.

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.

Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM.

Blood Cells Mol Dis. 2009 Jul-Aug;43(1):119-28. doi: 10.1016/j.bcmd.2009.01.019. Epub 2009 Mar 17.

PMID:
19297219
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.

Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC.

Pediatr Blood Cancer. 2014 Jun;61(6):1055-62. doi: 10.1002/pbc.24932. Epub 2014 Jan 29.

PMID:
24474498
[PubMed - indexed for MEDLINE]
10.

The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.

Tomek A, Maťoška V, Kolářová T, Neumann J, Srámek M, Sarbochová I, Táborský L, Bojar M, Goetz P, Serebruany VL.

Cardiology. 2013;125(3):182-91. doi: 10.1159/000350407. Epub 2013 Jun 12.

PMID:
23774101
[PubMed - indexed for MEDLINE]
11.

Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.

Krishna Kumar D, Shewade DG, Loriot MA, Beaune P, Balachander J, Sai Chandran BV, Adithan C.

Eur J Clin Pharmacol. 2014 Jan;70(1):47-56. doi: 10.1007/s00228-013-1581-x. Epub 2013 Sep 10.

PMID:
24019055
[PubMed - indexed for MEDLINE]
12.

Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.

Bazan NS, Sabry NA, Rizk A, Mokhtar S, Badary OA.

Ir J Med Sci. 2014 Jun;183(2):161-72. doi: 10.1007/s11845-013-0978-y. Epub 2013 Jun 27.

PMID:
23800980
[PubMed - indexed for MEDLINE]
13.

Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.

Molden E, Okkenhaug C, Ekker Solberg E.

Eur J Clin Pharmacol. 2010 May;66(5):525-30. doi: 10.1007/s00228-010-0813-6. Epub 2010 Mar 31.

PMID:
20354686
[PubMed - indexed for MEDLINE]
14.

Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations.

Gan GG, Phipps ME, Lee MM, Lu LS, Subramaniam RY, Bee PC, Chang SH.

Ann Hematol. 2011 Jun;90(6):635-41. doi: 10.1007/s00277-010-1119-6. Epub 2010 Nov 26.

PMID:
21110192
[PubMed - indexed for MEDLINE]
15.

Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.

Ye C, Jin H, Zhang R, Sun Y, Wang Z, Sun W, Sun W, Peng Q, Liu R, Huang Y.

J Int Med Res. 2014 Feb;42(1):67-76. doi: 10.1177/0300060513499094. Epub 2013 Nov 28.

PMID:
24287930
[PubMed - indexed for MEDLINE]
16.

Variability in CYP2C9 allele frequency: a pilot study of its predicted impact on warfarin response among healthy South and North Indians.

Nahar R, Deb R, Saxena R, Puri RD, Verma IC.

Pharmacol Rep. 2013;65(1):187-94.

PMID:
23563037
[PubMed - indexed for MEDLINE]
Free Article
17.

Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.

Liang R, Li L, Li C, Gao Y, Liu W, Hu D, Sun Y.

J Thromb Thrombolysis. 2012 Jul;34(1):120-5. doi: 10.1007/s11239-012-0725-7.

PMID:
22528326
[PubMed - indexed for MEDLINE]
18.

Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.

Miao L, Yang J, Huang C, Shen Z.

Eur J Clin Pharmacol. 2007 Dec;63(12):1135-41. Epub 2007 Sep 27.

PMID:
17899045
[PubMed - indexed for MEDLINE]
19.

CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.

Santos PC, Dinardo CL, Schettert IT, Soares RA, Kawabata-Yoshihara L, Bensenor IM, Krieger JE, Lotufo PA, Pereira AC.

Eur J Clin Pharmacol. 2013 Apr;69(4):789-97. doi: 10.1007/s00228-012-1404-5. Epub 2012 Sep 19.

PMID:
22990331
[PubMed - indexed for MEDLINE]
20.

Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.

Kim HS, Lee SS, Oh M, Jang YJ, Kim EY, Han IY, Cho KH, Shin JG.

Pharmacogenet Genomics. 2009 Feb;19(2):103-12. doi: 10.1097/FPC.0b013e32831a9ae3.

PMID:
19077919
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk